Back to results
US 2026/0083764 A1Published application
Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases
AssigneeN.V. Nutricia
InventorsSaskia Braber, Belinda Potappel - van 't Land, Selma Paulien Wiertsema, Johan Garssen, Bernd Stahl, Marko Mank
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.
Claims12
Infant formula, follow on formula or young child formula, comprising:
- a. 1.6 to 4 g protein based on 100 kcal,
- b. 5 to 20 g digestible carbohydrates based on 100 kcal,
- c. 3 to 7 g lipid based on 100 kcal, wherein the lipid comprises:
- i. LC-PUFA selected from the group consisting of DHA, EPA and ARA, wherein the sum of DHA, ARA and EPA is at least 1 wt % based on total fatty acids, and
- ii. at least 0.1 wt % EPA based on total fatty acids and at least 0.5 wt % DHA based on total fatty acids, and at least 0.25 wt % ARA based on total fatty acids,
- d. 0.25 to 2.5 g galacto-oligosaccharides per 100 ml of ready to drink formula, wherein the galacto-oligosaccharides comprise Gal (beta 1-3)-Gal (beta 1-4)-Glc in an amount of 10 to 50 mg per 100 ml ready to drink formula
- wherein the infant formula, follow on formula or young child formula is not human milk.
4 more elements
Dependencies are inferred from the claim text.